
  
    
      
        Introduction_NNP
        Common_JJ agents_NNS currently_RB used_VBN in_IN treating_VBG metastatic_JJ
        breast_NN cancer_NN are_VBP the_DT antimitotics_NNS paclitaxel_NN and_CC docetaxel_NN
        [_NN 1_CD 2_CD ]_NN ._. These_DT drugs_NNS bind_NN to_TO β-tubulin_JJ ,_, a_DT major_JJ protein_NN in_IN
        mitotic_JJ spindles_NNS ,_, and_CC halt_NN cell_NN division_NN at_IN metaphase_NN ._.
        Their_PRP$ effectiveness_NN in_IN cancer_NN chemotherapy_NN is_VBZ thought_VBN to_TO be_VB
        due_JJ to_TO their_PRP$ ability_NN to_TO reduce_VB the_DT dynamics_NNS of_IN microtubules_NNS
        in_IN mitotic_JJ spindles_NNS ,_, thus_RB preventing_VBG spindle_NN assembly_NN and_CC
        interrupting_VBG the_DT normal_JJ movement_NN of_IN sister_NN chromatids_NNS
        toward_IN the_DT spindle_NN poles_NNS [_NN 3_CD 4_CD 5_CD 6_CD 7_CD 8_CD 9_CD ]_NN ._. Tubulin_NNP ,_, a_DT 100_CD
        kDa_NN αβ_NN heterodimer_NN ,_, is_VBZ structurally_RB heterogeneous_JJ ,_, with_IN
        seven_CD genes_NNS encoding_VBG α-tubulin_JJ and_CC β-tubulin_JJ isotypes_NNS ._. The_DT
        major_JJ differences_NNS between_IN isotype_NN classes_NNS reside_VB in_IN the_DT
        last_JJ 15_CD -_: 20_CD amino_JJ acids_NNS of_IN the_DT carboxy-termini_JJ [_NN 10_CD 11_CD ]_NN ,_,
        and_CC these_DT differences_NNS have_VBP been_VBN exploited_VBN in_IN the_DT
        development_NN of_IN isotype-specific_JJ antibodies_NNS [_NN 12_CD 13_CD 14_CD ]_NN ._.
        Mammalian_NNP microtubules_NNS are_VBP formed_VBN from_IN a_DT mixture_NN of_IN
        α-tubulin_JJ and_CC β-tubulin_JJ isotype_NN classes_NNS [_NN 11_CD 15_CD 16_CD ]_NN ,_, and_CC
        the_DT antimitotics_NNS used_VBN in_IN chemotherapy_NN interact_NN primarily_RB
        with_IN β-tubulin_JJ ._. In_IN vertebrates_NNS the_DT concentrations_NNS of_IN the_DT
        specific_JJ isotypes_NNS vary_VBP in_IN different_JJ tissues_NNS [_NN 11_CD 17_CD ]_NN ,_,
        although_IN the_DT functional_JJ role_NN for_IN the_DT variability_NN in_IN tubulin_NN
        polypeptides_NNS is_VBZ uncertain_JJ [_NN 17_CD 18_CD ]_NN ._.
        The_DT expression_NN of_IN genes_NNS encoding_VBG α-tubulin_JJ and_CC β-tubulin_JJ
        seems_VBZ to_TO be_VB developmentally_RB regulated_VBN [_NN 19_CD ]_NN ._. For_IN example_NN ,_,
        tubulin_NN isotype_NN expression_NN patterns_NNS change_VBP during_IN the_DT
        development_NN and_CC maturation_NN of_IN neurons_NNS [_NN 14_CD 20_CD ]_NN ._. Studies_NNPS
        with_IN paclitaxel_NN or_CC other_JJ antimitotic_JJ agents_NNS ,_, such_JJ as_IN
        colchicine_NN or_CC estramustine_NN ,_, indicate_VBP that_IN drug_NN interactions_NNS
        with_IN tubulin_NN isotypes_NNS differ_VBP [_NN 21_CD 22_CD 23_CD 24_CD 25_CD ]_NN and_CC might_MD
        contribute_VB to_TO cell_NN resistance_NN to_TO antimitotics_NNS [_NN 26_CD 27_CD 28_CD 29_CD
        30_CD 31_CD ]_NN ._. However_RB ,_, one_CD group_NN of_IN antimitotic_JJ agents_NNS ,_, the_DT
        vinca_NN alkaloids_NNS ,_, was_VBD shown_VBN to_TO bind_NN with_IN similar_JJ affinity_NN to_TO
        all_DT tubulin_NN isotypes_NNS [_NN 12_CD ]_NN ,_, suggesting_VBG that_IN alterations_NNS
        in_IN drug_NN binding_JJ affinity_NN is_VBZ unlikely_JJ to_TO be_VB the_DT cause_NN of_IN
        drug_NN resistance_NN ._. Furthermore_RB ,_, whereas_IN some_DT of_IN these_DT data_NNS
        suggest_VBP a_DT role_NN for_IN tubulin_NN isotypes_NNS in_IN drug_NN resistance_NN ,_,
        cell_NN growth_NN ,_, and_CC differentiation_NN ,_, other_JJ work_NN indicates_VBZ that_IN
        isotype-independent_JJ factors_NNS affecting_VBG micro-tubule_JJ polymer_NN
        formation_NN are_VBP more_RBR important_JJ than_IN changes_NNS in_IN isotype_NN levels_NNS
        [_NN 32_CD 33_CD 34_CD 35_CD ]_NN ._. For_IN example_NN ,_, a_DT decrease_NN in_IN total_JJ polymer_NN
        concentrations_NNS causes_NNS resistance_NN to_TO microtubule-stabilizing_JJ
        agents_NNS such_JJ as_IN paclitaxel_NN [_NN 34_CD 35_CD ]_NN ._.
        The_DT work_NN presented_VBN here_RB quantitatively_RB compares_VBZ the_DT
        tubulin_NN isotype_NN levels_NNS in_IN normal_JJ and_CC tumor_NN breast_NN tissues_NNS ._.
        We_PRP developed_VBD an_DT indirect_JJ ,_, competitive_JJ enzyme-linked_JJ
        immunosorbent_NN assay_NN (_( ELISA_NNP )_) using_VBG antibodies_NNS specific_JJ for_IN
        β-tubulin_JJ classes_NNS II_NNP ,_, III_NNP and_CC I_PRP +_NN IV_NNP that_WDT is_VBZ sensitive_JJ to_TO 1_CD
        μg_NN /_NN ml_NN tubulin_NN ._. The_DT results_NNS of_IN the_DT ELISA_NNP assay_NN agree_VBP with_IN
        quantitative_JJ Western_NNP blotting_VBG and_CC indicate_VBP that_IN β-tubulin_JJ
        class_NN II_NNP predominates_NNS in_IN both_DT normal_JJ and_CC tumor_NN breast_NN
        tissues_NNS ._. Isotype_NNP levels_NNS are_VBP similar_JJ in_IN both_DT tissues_NNS ,_, but_CC
        surprisingly_RB they_PRP exhibit_NN a_DT broad_JJ fractional_JJ distribution_NN ._.
        To_TO explore_VB this_DT further_RBR we_PRP measured_VBD Her_PRP$ 2_CD /_NN neu_NN protein_NN
        levels_NNS ,_, which_WDT are_VBP known_VBN to_TO be_VB correlated_JJ with_IN poor_JJ
        prognosis_NN ._. We_PRP demonstrate_VBP that_IN although_IN Her_PRP$ 2_CD /_NN neu_NN levels_NNS in_IN
        tumor_NN tissues_NNS were_VBD 5_CD -_: 30_CD -_: fold_VB those_DT in_IN normal_JJ tissues_NNS ,_, there_EX
        was_VBD no_DT correlation_NN between_IN the_DT Her_PRP$ 2_CD /_NN neu_NN biomarker_NN and_CC
        tubulin_NN isotype_NN levels_NNS ._. Taken_VBN together_RB ,_, these_DT data_NNS suggest_VBP
        that_IN ,_, unlike_IN previous_JJ reports_NNS on_IN small_JJ cell_NN lung_NN cancer_NN [_NN
        36_CD ]_NN ,_, β-tubulin_JJ isotype_NN levels_NNS are_VBP not_RB diagnostic_JJ markers_NNS
        in_IN breast_NN cancer_NN ._. These_DT results_NNS challenge_VBP the_DT hypothesis_NNS of_IN
        a_DT universal_JJ role_NN for_IN tubulin_NN isotypes_NNS in_IN tumor_NN growth_NN and_CC
        the_DT development_NN of_IN drug_NN resistance_NN ._. Nevertheless_RB ,_, we_PRP cannot_NN
        exclude_VBP the_DT possibility_NN that_IN changes_NNS in_IN the_DT distribution_NN of_IN
        tubulin_NN isotypes_NNS in_IN normal_JJ and_CC tumor_NN breast_NN tissue_NN ,_, in_IN
        conjunction_NN with_IN other_JJ molecular_JJ factors_NNS ,_, might_MD still_RB be_VB
        relevant_JJ to_TO disease_NN progression_NN and_CC cellular_JJ response_NN to_TO
        antimitotic_JJ drugs_NNS ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Reagents_NNP
          MgSO_NNP 
          4_CD ,_, (_( ethylene-bis_JJ
          [_NN oxyethylenenitrilo_NN ]_NN )_) tetraacetic_JJ acid_NN (_( EGTA_NNP )_) ,_, GTP_NNP (_( type_NN
          II-S_NNP )_) ,_, glycerol_NN ,_, 2_CD -_: (_( 
          N_NNP -_: morpholino_NN )_) -_: ethane_NN sulfonic_JJ acid_NN
          (_( MES_NNP )_) ,_, Nonidet_NNP P_NN 40_CD ,_, piperazine-_NN 
          N_NNP ,_, N_NNP '_POS -_: bis_NNS (_( 2_CD -_: ethanesulfonic_JJ acid_NN )_)
          (_( PIPES_NNP )_) and_CC Triton_NNP X-_NNP 100_CD were_VBD purchased_VBN from_IN Sigma_NNP
          Chemical_NNP Company_NNP ._. Sephadex_NNP G-_NNP 50_CD was_VBD from_IN Pharmacia_NNP ._. Nitro_NNP
          blue_JJ tetrazolium_NN (_( NBT_NNP )_) ,_, 5_CD -_: bromo-_NN 4_CD -_: chloroindol-_NN 3_CD -_: yl_NN
          phosphate_NN (_( BCIP_NNP )_) and_CC poly_RB (_( vinylidene_NN difluoride_NN )_) (_( PVDF_NNP )_)
          were_VBD from_IN Bio-_NNP Rad_NNP ._. Deionized_NNP (_( Nanopure_NNP )_) water_NN was_VBD used_VBN in_IN
          all_DT experiments_NNS ._.
        
        
          Purification_NNP of_IN tubulin_NN from_IN pig_NN brain_NN
          Phosphocellulose-purified_NNP tubulin_NN (_( PC-tubulin_NNP )_) free_JJ of_IN
          microtubule-associated_JJ proteins_NNS (_( MAPs_NNP )_) was_VBD obtained_VBN by_IN
          warm_JJ /_NN cold_JJ polymerization_NN /_NN depolymerization_NN with_IN the_DT
          addition_NN of_IN a_DT final_JJ phosphocellulose_NN chromatography_NN step_NN
          to_TO separate_VB tubulin_NN from_IN MAPs_NNP [_NN 37_CD 38_CD ]_NN ._. Tubulin_NNP
          concentrations_NNS were_VBD determined_VBN spectrophotometrically_RB ,_,
          using_VBG ε_NN 
          278_CD =_SYM 1_CD ._. 2_CD L_NNP /_NN (_( g_SYM cm_NN )_) [_NN 39_CD ]_NN ._.
        
        
          Cell_NNP culture_NN and_CC Her_PRP$ 2_CD /_NN neu_NN ELISAs_NNP
          The_DT breast_NN cancer_NN cell_NN lines_NNS MCF-_NNP 7_CD and_CC HCC_NNP 1954_CD were_VBD
          obtained_VBN from_IN American_NNP Type_NNP Culture_NNP Collection_NNP and_CC grown_VBN
          under_IN the_DT recommended_VBN conditions_NNS ._. MCF-_NNP 7_CD cells_NNS are_VBP known_VBN
          to_TO have_VB fewer_JJR than_IN five_CD copies_NNS of_IN the_DT Her_PRP$ 2_CD /_NN neu_NN gene_NN ,_,
          whereas_IN HCC_NNP 1954_CD cells_NNS overexpress_NNS the_DT protein_NN because_IN of_IN
          gene_NN amplification_NN [_NN 40_CD 41_CD ]_NN ._. Her_PRP$ 2_CD /_NN neu_NN protein_NN levels_NNS
          were_VBD determined_VBN with_IN a_DT Her_PRP$ 2_CD /_NN neu_NN ELISA_NNP kit_NN (_( Oncogene_NNP )_) in_IN
          accordance_NN with_IN the_DT manufacturer_NN 's_POS instructions_NNS ._. This_DT
          ELISA_NNP kit_NN was_VBD also_RB used_VBN to_TO determine_VB Her_PRP$ 2_CD /_NN neu_NN protein_NN
          levels_NNS in_IN tissue_NN samples_NNS ._.
        
        
          Tissue_NNP preparation_NN and_CC tubulin_NN fractionation_NN
          Anonymous_NNP paired_VBN tumor_NN (_( 
          n_NN =_SYM 20_CD )_) and_CC normal_JJ (_( 
          n_NN =_SYM 20_CD )_) breast_NN tissue_NN samples_NNS
          (_( 0_CD ._. 25_CD -_: 1_CD ._. 0_CD g_SYM )_) ,_, quick-frozen_JJ in_IN liquid_JJ nitrogen_NN within_IN 1_CD
          hour_NN of_IN surgery_NN ,_, were_VBD provided_VBN by_IN the_DT Cooperative_NNP Human_NNP
          Tissue_NNP Network_NNP (_( CHTN_NNP ,_, National_NNP Cancer_NNP Institute_NNP )_) (_( Table_NNP
          1_LS )_) ._. Pathology_NNP reports_NNS were_VBD provided_VBN by_IN CHTN_NNP for_IN each_DT
          tissue_NN sample_NN ._. Only_RB primary_JJ tumor_NN samples_NNS were_VBD examined_VBN ._.
          Normal_NNP tissue_NN was_VBD taken_VBN from_IN the_DT same_JJ breast_NN at_IN a_DT site_NN
          distant_JJ from_IN the_DT tumor_NN and_CC evaluated_VBN for_IN the_DT presence_NN of_IN
          tumor_NN cells_NNS ._. The_DT patients_NNS in_IN the_DT study_NN ,_, ages_NNS ranging_VBG from_IN
          28_CD to_TO 92_CD years_NNS ,_, had_VBD not_RB received_VBN prior_RB radiation_NN or_CC
          chemotherapy_NN ._. The_DT diagnosis_NN of_IN each_DT patient_NN is_VBZ shown_VBN in_IN
          Table_NNP 1_CD ._. Tissue_NNP samples_NNS were_VBD homogenized_JJ in_IN a_DT Dounce_NNP
          homogenizer_NN on_IN ice_NN in_IN 1_CD ml_NN of_IN lysis_NNS buffer_NN (_( 25_CD mM_NN MES_NNP ,_, 1_CD
          mM_NN MgSO_NNP 
          4_CD ,_, 2_CD mM_NN EGTA_NNP ,_, 0_CD ._. 1_CD mM_NN GTP_NNP ,_, 0_CD ._. 1_CD %_NN Triton_NNP
          X-_NNP 100_CD with_IN a_DT protease_NN inhibitor_NN cocktail_NN [_NN Complete_JJ
          Protease_NNP Inhibitor_NNP Tablets_NNP ;_: Boehringer_NNP Mannheim_NNP ]_NN )_) ._.
          Membranes_NNP were_VBD removed_VBN by_IN pelleting_VBG at_IN 4_CD °_NN C_NNP in_IN a_DT
          micro-centrifuge_JJ for_IN 5_CD min_NN ._. Membrane_NNP lipids_NNS remained_VBD at_IN
          the_DT top_NN of_IN the_DT sample_NN and_CC a_DT tiny_JJ pellet_NN was_VBD often_RB also_RB
          observed_VBD ._. The_DT pellet_NN was_VBD not_RB sufficiently_RB large_JJ to_TO allow_VB
          the_DT determination_NN of_IN protein_NN levels_NNS with_IN our_PRP$ assay_NN ._. The_DT
          total_JJ protein_NN concentration_NN in_IN the_DT supernatant_NN (_( separated_JJ
          from_IN the_DT lipid_NN fraction_NN )_) was_VBD determined_VBN with_IN the_DT Advanced_NNP
          Protein_NNP Assay_NNP Reagent_NNP (_( Cytoskeleton_NNP Inc_NNP )_) ._. The_DT supernatant_NN
          was_VBD then_RB loaded_VBN on_IN a_DT 2_CD ml_NN arginine-_NN Sepharose_NNP column_NN
          equilibrated_JJ with_IN the_DT MES_NNP buffer_NN above_IN without_IN Triton_NNP
          X-_NNP 100_CD ._. The_DT procedure_NN for_IN arginine-_NN Sepharose_NNP purification_NN
          of_IN tubulin_NN was_VBD presented_VBN in_IN detail_NN by_IN Lacey_NNP and_CC Snowdon_NNP [_NN
          42_CD ]_NN ._. An_DT enriched_JJ tubulin_NN fraction_NN was_VBD collected_VBN in_IN
          high-salt_JJ MES_NNP buffer_NN (_( 2_CD ._. 5_LS %_NN ammonium_NN sulphate_NN )_) and_CC
          equilibrated_JJ in_IN 10_CD mM_NN Pipes_NNP ,_, pH_NN 6_CD ._. 9_CD ,_, 2_CD mM_NN EGTA_NNP ,_, 1_CD mM_NN MgSO_NNP
          
          4_LS ,_, 0_CD ._. 05_CD mM_NN GDP_NNP ,_, 0_CD ._. 01_CD %_NN Triton_NNP X-_NNP 100_CD ,_,
          using_VBG a_DT spun_VBN column_NN ._. The_DT tubulin_NN fractions_NNS were_VBD used_VBN in_IN
          the_DT ELISA_NNP and_CC /_NN or_CC Western_NNP blotting_VBG experiments_NNS ._. The_DT same_JJ
          procedure_NN was_VBD used_VBN to_TO fractionate_NN pig_NN brain_NN samples_NNS to_TO
          quantify_VB tubulin_NN isotypes_NNS by_IN Western_NNP blotting_VBG ._.
          To_TO ensure_VB that_DT arginine-_NN Sepharose_NNP chromatography_NN did_VBD
          not_RB preferentially_RB fractionate_NN specific_JJ tubulin_NN isotypes_NNS ,_,
          microtubule_NN protein_NN fractions_NNS from_IN an_DT early_JJ stage_NN in_IN
          purification_NN (_( tubulin_NN plus_CC MAPs_NNP )_) were_VBD examined_VBN by_IN ELISAs_NNP
          and_CC Western_NNP blotting_VBG ._. There_EX were_VBD no_DT differences_NNS before_IN
          and_CC after_IN arginine-_NN Sepharose_NNP fractionation_NN in_IN the_DT
          percentages_NNS of_IN any_DT of_IN the_DT β-tubulin_JJ isotypes_NNS tested_VBN in_IN
          this_DT study_NN (_( data_NNS not_RB shown_VBN )_) ._.
        
        
          Quantitative_NNP Western_NNP blotting_VBG
          The_DT monoclonal_NN antibodies_NNS used_VBN in_IN the_DT studies_NNS ,_, TUJ_NNP 1_CD
          (_( anti-β-tubulin_JJ class_NN III_NNP )_) ,_, 7_CD H_NNP 12_CD (_( anti-β-tubulin_JJ classes_NNS
          I_PRP +_NN IV_NNP )_) ,_, and_CC 7_CD B_NNP 9_CD (_( anti-β-tubulin_JJ class_NN II_NNP )_) ,_, have_VBP been_VBN
          characterized_VBN previously_RB [_NN 13_CD 14_CD ]_NN and_CC are_VBP highly_RB
          specific_JJ for_IN their_PRP$ epitopes_NNS ._. Sequential_NNP immunoaffinity_NN
          columns_NNS were_VBD used_VBN to_TO purify_NN β-tubulin_JJ classes_NNS II_NNP and_CC III_NNP
          with_IN their_PRP$ associated_VBN α-tubulins_JJ as_IN described_VBN previously_RB
          [_NN 12_CD ]_NN ._. Known_VBN amounts_NNS of_IN PC-tubulin_NNP ,_, β-tubulin_JJ classes_NNS
          II_NNP and_CC III_NNP ,_, and_CC pig_NN brain_NN samples_NNS (_( 
          n_NN =_SYM 12_CD )_) from_IN the_DT cerebellum_NN and_CC
          right_JJ cerebrum_NN were_VBD examined_VBN by_IN SDS-polyacrylamide-gel_NNP
          electrophoresis_NNS and_CC transferred_VBN to_TO PVDF_NNP filters_NNS [_NN 43_CD ]_NN ._.
          Alkaline_NNP phosphatase_NN colorimetric_JJ reactions_NNS (_( NBT_NNP and_CC
          BCIP_NNP )_) were_VBD used_VBN to_TO identify_VB tubulin_NN isotypes_NNS ._. Triplicate_NNP
          blots_NNS for_IN each_DT sample_NN were_VBD analyzed_VBN by_IN densitometry_NN
          (_( Molecular_NNP Dynamics_NNP with_IN ImageQuant_NNP Software_NNP )_) ._. The_DT
          linearity_NN of_IN response_NN was_VBD established_VBN by_IN systematically_RB
          varying_VBG the_DT amounts_NNS of_IN known_VBN tubulin_NN loaded_VBN into_IN wells_NNS
          and_CC plotting_VBG these_DT values_NNS against_IN densitometry_NN results_NNS by_IN
          using_VBG Origin_NNP 5_CD ._. 0_CD (_( Microcal_NNP )_) ._. These_DT comparisons_NNS allowed_VBD us_PRP
          to_TO calibrate_NN the_DT amounts_NNS of_IN β-tubulin_JJ classes_NNS I_PRP +_NN IV_NNP ,_, II_NNP ,_,
          and_CC III_NNP in_IN PC-tubulin_NNP and_CC in_IN pig_NN brain_NN samples_NNS (_( Table_NNP 2_LS )_) ._.
          The_DT same_JJ procedures_NNS were_VBD used_VBN to_TO quantify_VB β-tubulin_JJ in_IN
          five_CD tumor_NN and_CC normal_JJ breast_NN tissues_NNS for_IN comparison_NN with_IN
          the_DT ELISA_NNP results_NNS ._.
        
        
          Tubulin_NNP isotype_NN ELISAs_NNP
          Indirect_JJ ,_, competitive_JJ ELISAs_NNP were_VBD used_VBN to_TO quantify_VB the_DT
          tubulin_NN isotypes_NNS in_IN tissue_NN samples_NNS ._. The_DT method_NN is_VBZ adapted_VBN
          from_IN standard_JJ protocols_NNS for_IN indirect_JJ ELISAs_NNP [_NN 44_CD ]_NN ._. The_DT
          indirect_JJ ELISA_NNP involves_VBZ the_DT titration_NN of_IN antibodies_NNS
          reacted_VBD with_IN tubulin_NN in_IN solution_NN ._. A_DT known_VBN amount_NN of_IN
          tubulin_NN is_VBZ mixed_VBN with_IN the_DT unknown_JJ sample_NN ;_: the_DT antibodies_NNS
          compete_VBP with_IN a_DT known_VBN amount_NN of_IN tubulin_NN bound_VBN to_TO the_DT
          plate_NN ._. A_DT secondary_JJ antibody_NN generates_VBZ the_DT signal_NN used_VBN to_TO
          quantify_VB the_DT unknown_JJ protein_NN ._. The_DT amount_NN of_IN known_VBN protein_NN
          can_MD be_VB adjusted_VBN to_TO optimize_NN the_DT sensitivity_NN of_IN the_DT
          assay_NN ._.
          Optimal_NNP tubulin_NN binding_JJ (_( 75_CD μg_NN /_NN ml_NN ,_, 50_CD μl_NN per_IN well_RB )_) to_TO
          polystyrene_NN microtiter_NN plates_NNS (_( 96_CD wells_NNS ;_: Nalge_NNP NUNC_NNP
          International_NNP )_) was_VBD performed_VBN overnight_JJ at_IN 4_CD °_NN C_NNP in_IN a_DT humid_JJ
          environment_NN ._. Plates_NNP were_VBD then_RB washed_VBN three_CD times_NNS with_IN
          phosphate-buffered_JJ saline_NN (_( PBS_NNP )_) and_CC blotted_JJ dry_JJ ._. The_DT
          average_JJ values_NNS in_IN pig_NN brain_NN tissues_NNS for_IN each_DT isotype_NN (_( 53_CD %_NN
          β_NN class_NN II_NNP ,_, 17_CD %_NN β_NN classes_NNS I_PRP +_NN IV_NNP ,_, and_CC 29_CD %_NN β_NN class_NN III_NNP ;_:
          determined_VBN as_IN described_VBN above_IN ;_: Table_NNP 2_LS )_) were_VBD used_VBN to_TO
          construct_VB standard_JJ curves_NNS in_IN the_DT tubulin_NN isotype_NN ELISA_NNP
          assay_NN ._. Duplicate_NNP standard_JJ curves_NNS for_IN each_DT antibody_NN were_VBD
          made_VBN with_IN PC-tubulin_NNP (_( final_JJ concentration_NN 150_CD μg_NN /_NN ml_NN ,_, 3_CD %_NN
          nonfat_JJ dried_VBD milk_NN in_IN PBS_NNP )_) ._. Duplicate_NNP unknown_JJ tissue_NN
          samples_NNS were_VBD prepared_VBN by_IN combining_VBG them_PRP with_IN known_VBN levels_NNS
          of_IN PC-tubulin_NNP (_( 1_CD :_: 1_LS )_) ,_, then_RB mixing_VBG them_PRP 1_CD :_: 1_CD with_IN
          antibody_NN in_IN 3_CD %_NN nonfat_JJ dried_VBD milk_NN in_IN PBS_NNP ._.
          Antibodies_NNP (_( usually_RB about_IN 1_CD mg_NN /_NN ml_NN )_) against_IN β-tubulin_JJ
          classes_NNS I_PRP +_NN IV_NNP (_( 7_CD H_NNP 12_CD )_) ,_, II_NNP (_( 7_CD B_NNP 9_CD )_) ,_, and_CC III_NNP (_( TUJ_NNP 1_LS )_) were_VBD used_VBN
          at_IN optimal_NN dilutions_NNS (_( ranging_VBG from_IN 1_CD :_: 500_CD to_TO 1_CD :_: 10000_CD )_)
          determined_VBN empirically_RB for_IN each_DT new_JJ stock_NN of_IN antibody_NN ._.
          Serial_JJ dilutions_NNS (_( 50_CD μl_NN per_IN well_RB )_) were_VBD performed_VBN ,_, varying_VBG
          only_RB the_DT protein_NN concentration_NN and_CC keeping_VBG the_DT antibody_NN
          and_CC nonfat_JJ dried_VBD milk_NN concentrations_NNS constant_JJ ._. Plates_NNP
          were_VBD left_VBN at_IN 22_CD °_NN C_NNP under_IN mild_JJ humidity_NN for_IN 2_CD hours_NNS on_IN a_DT
          shaker_NN and_CC then_RB washed_VBN four_CD times_NNS with_IN PBS_NNP and_CC blotted_JJ
          dry_JJ before_IN addition_NN of_IN the_DT secondary_JJ horseradish_NN
          peroxidase-conjugated_JJ antibody_NN (_( Sigma_NNP )_) in_IN 3_CD %_NN nonfat_JJ dried_VBD
          milk_NN in_IN PBS_NNP ._. Secondary_JJ antibody_NN concentrations_NNS were_VBD
          optimized_JJ for_IN each_DT new_JJ stock_NN ._. After_IN 2_CD hours_NNS at_IN 22_CD °_NN C_NNP on_IN a_DT
          shaker_NN ,_, plates_NNS were_VBD washed_VBN four_CD times_NNS with_IN PBS_NNP ,_, blotted_JJ
          dry_JJ and_CC reacted_VBD with_IN tetramethylbenzidine_NN (_( 50_CD μl_NN per_IN
          well_RB )_) ._. The_DT reaction_NN was_VBD stopped_VBN with_IN 1_CD M_NNP sulfuric_JJ acid_NN ,_,
          and_CC plates_NNS were_VBD read_VBN at_IN 450_CD nm_NN in_IN a_DT 96_CD -_: well_RB plate_NN reader_NN
          (_( TECAN_NNP ,_, Research_NNP Triangle_NNP Park_NNP ,_, North_NNP Carolina_NNP )_) ._.
          Data_NNP were_VBD fitted_JJ by_IN nonlinear_NN least_JJS squares_NNS ,_, using_VBG
          Fitall_NNP (_( MTR_NNP software_NN ,_, Toronto_NNP ,_, Canada_NNP )_) modified_VBN with_IN an_DT
          exponential_NN fitting_JJ function_NN ._. This_DT fitter_NN globally_RB fits_VBZ
          the_DT standard_JJ curve_NN and_CC the_DT sample_NN data_NN to_TO extract_VB the_DT
          amplitude_NN ,_, the_DT exponential_NN curvature_NN ,_, and_CC the_DT amount_NN of_IN
          tubulin_NN isotype_NN in_IN the_DT breast_NN tissue_NN sample_NN ._. Typical_JJ
          ELISA_NNP data_NNS are_VBP shown_VBN in_IN Fig_NNP ._. 1_LS ._. In_IN developing_VBG the_DT
          quantitative_JJ tubulin_NN ELISA_NNP ,_, either_CC microtubule_NN protein_NN
          from_IN pig_NN brain_NN containing_VBG unknown_JJ amounts_NNS of_IN tubulin_NN or_CC a_DT
          known_VBN amount_NN of_IN PC-tubulin_NNP was_VBD used_VBN as_IN the_DT experimental_JJ
          sample_NN ._. This_DT permitted_VBD a_DT determination_NN of_IN the_DT accuracy_NN of_IN
          our_PRP$ quantification_NN ._. The_DT experiments_NNS with_IN microtubule_NN
          protein_NN resulted_VBD in_IN isotype_NN percentages_NNS similar_JJ to_TO those_DT
          determined_VBN by_IN quantitative_JJ Western_NNP blotting_VBG ._. Isotype_NNP
          determinations_NNS with_IN the_DT experimental_JJ samples_NNS made_VBN with_IN
          known_VBN PC-tubulin_NNP were_VBD ,_, within_IN error_NN ,_, the_DT same_JJ as_IN the_DT
          expected_VBN quantities_NNS (_( data_NNS not_RB shown_VBN )_) ._.
          The_DT reliability_NN of_IN the_DT tubulin_NN ELISA_NNP is_VBZ indicated_VBN by_IN
          comparison_NN with_IN quantitative_JJ Western_NNP blotting_VBG of_IN breast_NN
          tissue_NN samples_NNS (_( Figs_NNP 2_CD and_CC 3_LS )_) ._. Five_CD paired_VBN anonymous_JJ
          normal_JJ and_CC anonymous_JJ tumor_NN samples_NNS were_VBD obtained_VBN in_IN 1_CD -_: 2_CD g_SYM
          quantities_NNS sufficient_JJ for_IN quantitative_JJ Western_NNP blotting_VBG
          (_( kindly_RB provided_VBN by_IN Dr_NNP Terry_NNP Hall_NNP ,_, University_NNP of_IN
          Mississippi_NNP Medical_NNP Center_NNP ,_, Jackson_NNP ,_, Mississippi_NNP )_) ._. There_EX
          is_VBZ no_DT significant_JJ difference_NN between_IN normal_JJ and_CC tumor_NN
          tissue_NN distributions_NNS of_IN tubulin_NN isotypes_NNS ._. However_RB ,_,
          β-tubulin_JJ classes_NNS II_NNP and_CC I_PRP +_NN IV_NNP fractions_NNS vary_VBP widely_RB :_:
          0_CD ._. 23_CD -_: 0_CD ._. 54_CD and_CC 0_CD ._. 20_CD -_: 0_CD ._. 67_CD ,_, respectively_RB ._. β-_NN Tubulin_NNP class_NN
          III_NNP values_NNS are_VBP relatively_RB constant_JJ ,_, 0_CD ._. 20_CD -_: 0_CD ._. 27_CD (_( with_IN the_DT
          exception_NN of_IN one_CD pair_NN ,_, 0_CD ._. 09_CD and_CC 0_CD ._. 11_CD for_IN tumor_NN [_NN T_NN 4_CD ]_NN and_CC
          normal_JJ [_NN N_NNP 4_CD ]_NN ;_: Fig_NNP ._. 3_LS )_) ._. These_DT wide_JJ distributions_NNS for_IN
          β-tubulin_JJ classes_NNS II_NNP and_CC I_PRP +_NN IV_NNP agree_VBP with_IN the_DT ELISAs_NNP for_IN
          the_DT larger_JJR study_NN of_IN 40_CD additional_JJ samples_NNS from_IN CHTN_NNP
          presented_VBD here_RB (_( 0_CD ._. 41_CD -_: 0_CD ._. 76_CD and_CC 0_CD ._. 10_CD -_: 0_CD ._. 46_CD ,_, respectively_RB )_) ._.
          Note_VB also_RB that_RB ,_, unlike_IN for_IN breast_NN tissues_NNS ,_, quantitative_JJ
          Western_JJ blot_NN analyses_NNS of_IN pig_NN brain_NN samples_NNS demonstrate_VBP
          relatively_RB constant_JJ tubulin_NN isotype_NN fractions_NNS described_VBD
          above_IN (_( Table_NNP 2_LS )_) ._. The_DT values_NNS for_IN each_DT isotype_NN in_IN pig_NN brain_NN
          are_VBP in_IN reasonable_JJ agreement_NN with_IN the_DT values_NNS previously_RB
          reported_VBD (_( 58_CD %_NN ,_, 25_CD %_NN ,_, and_CC 13_CD %_NN for_IN β-tubulin_JJ classes_NNS II_NNP ,_,
          III_NNP ,_, and_CC IV_NNP )_) [_NN 45_CD ]_NN ,_, further_JJ establishing_VBG the_DT validity_NN
          of_IN this_DT approach_NN ._. This_DT result_NN supports_VBZ the_DT accuracy_NN and_CC
          the_DT sensitivity_NN of_IN the_DT quantitative_JJ Western_JJ blots_NNS and_CC
          ELISAs_NNP and_CC demonstrates_VBZ that_IN the_DT wide_JJ distribution_NN
          observed_VBD for_IN β-tubulin_JJ classes_NNS II_NNP and_CC I_PRP +_NN IV_NNP in_IN breast_NN
          tissues_NNS is_VBZ not_RB due_JJ to_TO error_NN in_IN measurement_NN ._.
        
        
          Immunohistochemistry_NNP
          Tissues_NNPS were_VBD fixed_VBN in_IN 10_CD %_NN buffered_JJ formalin_NN containing_VBG
          2_CD %_NN zinc_NN sulfate_NN to_TO preserve_VB antigenic_JJ sites_NNS ,_, then_RB
          embedded_VBN in_IN paraffin_NN ,_, and_CC sectioned_JJ on_IN a_DT Zeiss_NNP rotary_JJ
          microtome_NN ._. Trypsin_NNP digestion_NN was_VBD performed_VBN at_IN 22_CD °_NN C_NNP for_IN 15_CD
          min_NN and_CC followed_VBN by_IN a_DT wash_NN with_IN soybean_NN trypsin_NN
          inhibitor_NN ._. The_DT slides_NNS were_VBD de-paraffinized_JJ with_IN a_DT total_NN
          of_IN three_CD incubations_NNS in_IN xylene_NN ,_, rehydrated_JJ through_IN a_DT
          graded_JJ alcohol_NN series_NN beginning_VBG with_IN 100_CD %_NN ,_, 95_CD %_NN ,_, 70_CD %_NN ,_, and_CC
          50_CD %_NN in_IN PBS_NNP ,_, and_CC treated_VBD with_IN 0_CD ._. 3_CD %_NN hydrogen_NN peroxide_NN in_IN
          methanol_NN to_TO quench_NN the_DT endogenous_JJ peroxidase_NN activity_NN ._.
          The_DT sections_NNS were_VBD blocked_VBN in_IN 5_CD %_NN powdered_JJ skimmed_JJ milk_NN in_IN
          PBS_NNP (_( pH_NN 7_CD ._. 4_LS )_) and_CC incubated_JJ overnight_JJ in_IN a_DT humid_JJ chamber_NN
          at_IN 4_CD °_NN C_NNP with_IN primary_JJ monoclonal_NN antibodies_NNS ._. The_DT slides_NNS
          were_VBD washed_VBN with_IN four_CD changes_NNS of_IN PBS_NNP ,_, and_CC incubated_JJ with_IN
          a_DT working_VBG dilution_NN of_IN biotin-labeled_JJ anti-mouse_JJ secondary_JJ
          antibody_NN and_CC avidin-biotin-peroxidase_JJ complex_JJ (_( ABC_NNP )_) ._. The_DT
          color_NN was_VBD developed_VBN with_IN 17_CD mM_NN 3_CD '_POS ,_, 3_CD '_POS -_: diaminobenzidine_NN ,_, 40_CD
          mM_NN hydrogen_NN peroxide_NN in_IN 0_CD ._. 5_CD mM_NN Tris-_NNP HCl_NNP buffer_NN (_( pH_NN 5_CD ._. 0_CD )_) ._.
          The_DT sections_NNS were_VBD counterstained_JJ with_IN Gill_NNP 's_POS hematoxylin_NN ,_,
          dehydrated_JJ ,_, and_CC mounted_VBD ._. Negative_JJ controls_NNS were_VBD performed_VBN
          by_IN omission_NN of_IN the_DT primary_JJ antibody_NN ,_, and_CC positive_JJ
          controls_NNS for_IN tubulin_NN isotypes_NNS were_VBD performed_VBN with_IN pig_NN
          brain_NN tissues_NNS ._.
        
        
          Real-time_NNP polymerase_NN chain_NN reaction_NN (_( PCR_NNP )_)
          Real-time_NNP PCR_NNP was_VBD used_VBN to_TO determine_VB tubulin_NN isotype_NN
          mRNA_NN levels_NNS in_IN selected_VBN breast_NN tissues_NNS (_( Table_NNP 1_CD :_: T_NN 1_CD ,_, N_NNP 1_CD ,_,
          T_NN 4_CD ,_, N_NNP 4_CD ,_, T_NN 12_CD ,_, N_NNP 12_CD ,_, T_NN 13_CD ,_, N_NNP 13_CD ,_, T_NN 15_CD ,_, N_NNP 15_CD ,_, T_NN 18_CD ,_, N_NNP 18_CD ,_, N_NNP 6_CD ,_, and_CC
          T_NN 14_CD )_) ._. All_DT the_DT other_JJ breast_NN tissue_NN samples_NNS were_VBD required_VBN
          in_IN their_PRP$ entirety_NN for_IN the_DT ELISA_NNP and_CC immunohistochemistry_NN
          experiments_NNS ._. The_DT purpose_NN of_IN these_DT real-time_JJ PCR_NNP
          experiments_NNS was_VBD to_TO establish_VB whether_IN tubulin_NN protein_NN
          levels_NNS were_VBD correlated_JJ with_IN mRNA_NN levels_NNS ._. We_PRP developed_VBD
          protocols_NNS for_IN quantitative_JJ two-step_JJ reverse_NN transcriptase_NN
          PCR_NNP to_TO establish_VB the_DT relative_JJ amounts_NNS of_IN mRNA_NN transcripts_NNS
          encoding_VBG each_DT of_IN the_DT β-tubulin_JJ isotypes_NNS (_( classes_NNS I_PRP ,_, II_NNP ,_,
          III_NNP ,_, IVa_NNP ,_, IVb_NNP ,_, V_NNP ,_, and_CC VI_NNP )_) ._. Total_NNP RNA_NNP was_VBD extracted_VBN from_IN 5_CD
          ×_NN 10_CD 6_CD cells_NNS with_IN the_DT Micro-to-_NNP Midi_NNP ™_NN Total_NNP RNA_NNP
          Purification_NNP System_NNP (_( Invitrogen_NNP )_) ._. The_DT purity_NN of_IN the_DT RNA_NNP
          was_VBD assessed_VBN by_IN 
          A_DT 
          260_CD :_: 
          A_DT 
          280_CD ratios_NNS ._. Electrophoresis_NNP with_IN RNA_NNP
          6000_CD LabChips_NNP ™_NN and_CC an_DT Agilent_NNP 2100_CD Bioanalyzer_NNP was_VBD used_VBN
          to_TO determine_VB the_DT integrity_NN of_IN ribosomal_JJ RNA_NNP ._. The_DT RNA_NNP
          concentration_NN was_VBD calculated_VBN from_IN 
          A_DT 
          260_CD (_( 1_CD absorbance_NN unit_NN =_SYM 40_CD μg_NN /_NN ml_NN )_) or_CC
          obtained_VBN directly_RB from_IN the_DT bioanalyzer_NN ._. Before_IN the_DT
          reverse_JJ transcription_NN reaction_NN ,_, genomic_JJ DNA_NNP contamination_NN
          was_VBD eliminated_VBN by_IN digestion_NN with_IN deoxyribonuclease_NN I_PRP
          (_( amplification_NN grade_NN ;_: Sigma_NNP )_) ._.
          To_TO minimize_VB differences_NNS in_IN efficiency_NN of_IN the_DT reverse_JJ
          transcription_NN reaction_NN ,_, the_DT various_JJ isotype_NN complementary_JJ
          DNAs_NNP (_( cDNAs_NNS )_) were_VBD produced_VBN in_IN a_DT single_JJ tube_NN ._. Aliquots_NNP
          were_VBD then_RB used_VBN in_IN quantitative_JJ PCR_NNP to_TO determine_VB the_DT
          relative_JJ amount_NN of_IN each_DT isotype_NN cDNA_NN independently_RB ._. PCR_NNP
          reactions_NNS were_VBD performed_VBN with_IN isotype-specific_JJ primer_NN
          pairs_NNS for_IN β-tubulin_JJ isotype_NN classes_NNS I_PRP ,_, II_NNP ,_, III_NNP ,_, IVa_NNP ,_, and_CC
          IVb_NNP as_IN described_VBN [_NN 46_CD ]_NN ,_, with_IN minor_JJ modifications_NNS to_TO
          correct_JJ mismatches_NNS and_CC to_TO match_VB the_DT melting_VBG temperatures_NNS
          more_RBR closely_RB ._. Similar_JJ gene-specific_JJ primers_NNS were_VBD designed_VBN
          for_IN classes_NNS V_NNP and_CC VI_NNP (_( Table_NNP 3_LS )_) ._. In_IN preliminary_JJ
          experiments_NNS the_DT class_NN II_NNP primers_NNS gave_VBD rise_NN to_TO two_CD PCR_NNP
          products_NNS of_IN approximately_RB equal_JJ intensity_NN ,_, differing_VBG in_IN
          size_NN by_IN 30_CD base_NN pairs_NNS ._. These_DT two_CD products_NNS were_VBD cloned_VBN
          into_IN pCR-_NN 4_CD ,_, a_DT TA-cloning_NNP vector_NN ,_, and_CC subsequently_RB
          sequenced_JJ ._. The_DT results_NNS showed_VBD that_IN the_DT larger_JJR product_NN was_VBD
          due_JJ to_TO a_DT tandem_JJ duplication_NN at_IN the_DT reverse_JJ primer_NN ._. Thus_RB ,_,
          new_JJ primers_NNS for_IN the_DT β-tubulin_JJ class_NN II_NNP gene_NN were_VBD
          designed_VBN ._. β-_NN Tubulin_NNP cDNA_NN was_VBD produced_VBN with_IN gene-specific_JJ
          primers_NNS for_IN each_DT of_IN the_DT isotype_NN mRNAs_NNS and_CC Reflectase_NNP
          reverse_VB transcriptase_NN (_( Active_JJ Motif_NN )_) ._. Aliquots_NNP were_VBD used_VBN
          in_IN quantitative_JJ real-time_JJ PCR_NNP to_TO determine_VB independently_RB
          the_DT relative_JJ amount_NN of_IN each_DT isotype_NN cDNA_NN ._.
          To_TO obtain_VB control_NN cDNA_NN template_NN of_IN a_DT known_VBN quantity_NN
          for_IN generation_NN of_IN standard_JJ curves_NNS ,_, product_NN from_IN PCR_NNP
          reactions_NNS was_VBD isolated_VBN from_IN agarose_NN gels_NNS with_IN the_DT
          CONCERT_NNP ™_NN Rapid_NNP Gel_NNP Extraction_NNP kit_NN (_( Marligen_NNP )_) ._. The_DT
          concentration_NN of_IN purified_JJ cDNA_NN was_VBD determined_VBN by_IN
          analyzing_VBG serial_NN dilutions_NNS on_IN DNA_NNP 500_CD LabChips_NNP (_( Agilent_NNP )_) ._.
          Standard_JJ curves_NNS for_IN each_DT β-tubulin_JJ isotype_NN cDNA_NN were_VBD
          generated_VBN with_IN real-time_JJ PCR_NNP at_IN the_DT same_JJ time_NN as_IN data_NNS
          were_VBD collected_VBN for_IN each_DT of_IN the_DT tissue_NN samples_NNS ._. With_IN the_DT
          use_NN of_IN triplicate_NN samples_NNS and_CC no_DT template_NN controls_NNS ,_,
          real-time_JJ PCR_NNP (_( iCycler_NN ™_NN iQ_NN ;_: Bio-_NNP Rad_NNP )_) with_IN SYBR_NNP Green_NNP
          (_( Molecular_NNP Probes_NNP )_) as_IN the_DT detection_NN method_NN was_VBD performed_VBN
          to_TO quantify_VB the_DT mRNA_NN levels_NNS for_IN selected_VBN breast_NN tissues_NNS ._.
          The_DT amount_NN of_IN β-tubulin_JJ isotype_NN mRNA_NN in_IN a_DT known_VBN amount_NN of_IN
          total_JJ RNA_NNP was_VBD determined_VBN from_IN standard_JJ curves_NNS ._.
        
      
      
        Results_NNS
        
          Tubulin_NNP isotypes_NNS in_IN breast_NN tissues_NNS by_IN
          immunohistochemistry_NN
          A_DT total_NN of_IN 20_CD anonymous_JJ paired_VBN normal_JJ and_CC tumor_NN tissue_NN
          samples_NNS were_VBD obtained_VBN from_IN CHTN_NNP (_( Table_NNP 1_LS )_) ._. Selected_JJ
          breast_NN tissue_NN samples_NNS (_( 
          n_NN =_SYM 5_LS )_) were_VBD examined_VBN by_IN
          immunohistochemistry_NN for_IN the_DT presence_NN of_IN tubulin_NN
          isotypes_NNS ._. Thin_JJ sections_NNS from_IN all_DT five_CD samples_NNS (_( two_CD normal_JJ
          and_CC three_CD tumor_NN )_) reacted_VBD moderately_RB to_TO strongly_RB with_IN
          monoclonal_NN antibodies_NNS against_IN β-tubulin_JJ classes_NNS II_NNP and_CC I_PRP
          +_NN IV_NNP ._. Both_DT cellular_JJ and_CC stromal_NN staining_VBG were_VBD observed_VBN ._.
          Figure_NN 4_CD shows_VBZ sections_NNS from_IN a_DT tumor_NN sample_NN that_WDT had_VBD
          relatively_RB high_JJ levels_NNS of_IN β-tubulin_JJ class_NN III_NNP levels_NNS by_IN
          ELISA_NNP (_( Fig_NNP ._. 5_LS C_NNP :_: T_NN 18_CD )_) ._. Some_DT staining_VBG with_IN antibody_NN against_IN
          β-tubulin_JJ class_NN III_NNP was_VBD also_RB observed_VBN ,_, mostly_RB as_IN diffuse_NN
          background_NN stromal_NN tissue_NN staining_VBG (_( Fig_NNP ._. 4_LS C_NNP )_) ,_, although_IN
          occasionally_RB more_RBR specific_JJ reactivity_NN occurred_VBD ._. A_DT
          previous_JJ examination_NN of_IN five_CD normal_JJ and_CC tumor_NN breast_NN
          tissues_NNS showed_VBD similar_JJ staining_VBG patterns_NNS [_NN 47_CD ]_NN ._. In_IN that_DT
          study_NN ,_, antibodies_NNS against_IN β-tubulin_JJ classes_NNS II_NNP and_CC I_PRP +_NN IV_NNP
          also_RB reacted_VBD moderately_RB to_TO strongly_RB with_IN cells_NNS ,_, whereas_IN
          β-tubulin_JJ class_NN III_NNP was_VBD found_VBN in_IN stromal_NN cells_NNS and_CC rarely_RB
          in_IN punctate_NN ,_, irregular_JJ staining_VBG patterns_NNS ,_, suggesting_VBG
          cross_NN sections_NNS of_IN nerve_NN fibers_NNS ._. β-_NN Tubulin_NNP class_NN III_NNP in_IN
          normal_JJ tissues_NNS is_VBZ a_DT highly_RB specific_JJ marker_NN for_IN neurons_NNS [_NN
          10_CD 19_CD ]_NN and_CC we_PRP therefore_RB attribute_VBP most_JJS of_IN the_DT β-tubulin_JJ
          class_NN III_NNP antibody_NN reactivity_NN in_IN the_DT breast_NN tissues_NNS to_TO
          the_DT weak_JJ stromal_NN reactivity_NN and_CC presence_NN of_IN nerve_NN
          fibers_NNS ._.
        
        
          Quantification_NNP of_IN tubulin_NN isotypes_NNS in_IN breast_NN
          tissues_NNS by_IN ELISA_NNP
          To_TO quantify_VB tubulin_NN isotypes_NNS in_IN breast_NN tissue_NN samples_NNS
          (_( 0_CD ._. 25_CD -_: 1_CD ._. 0_CD g_SYM )_) we_PRP developed_VBD a_DT sensitive_JJ and_CC reliable_JJ
          indirect_JJ ELISA_NNP (_( sensitive_JJ to_TO levels_NNS of_IN 1_CD μg_NN /_NN ml_NN tubulin_NN
          isotype_NN )_) (_( Fig_NNP ._. 1_LS )_) ._. The_DT sensitivity_NN of_IN the_DT ELISA_NNP assay_NN was_VBD
          verified_VBN by_IN quantitative_JJ Western_NNP blotting_VBG (_( Figs_NNP 2_CD and_CC 3_LS )_) ._.
          These_DT results_NNS suggested_VBD that_IN β-tubulin_JJ classes_NNS II_NNP and_CC I_PRP +_NN
          IV_NNP are_VBP the_DT predominant_NN tubulin_NN isotypes_NNS in_IN these_DT tissues_NNS ._.
          This_DT was_VBD verified_VBN by_IN immunohistochemistry_NN (_( Fig_NNP ._. 4_LS )_) ,_, which_WDT
          demonstrated_VBD strong_JJ ,_, specific_JJ staining_VBG by_IN the_DT antibodies_NNS
          against_IN β-tubulin_JJ classes_NNS II_NNP and_CC I_PRP +_NN IV_NNP ._. In_IN the_DT work_NN
          presented_VBN here_RB ,_, each_DT tissue_NN sample_NN was_VBD examined_VBN in_IN
          duplicate_VB on_IN microtiter_NN plates_NNS ,_, and_CC triplicate_NN plates_NNS
          were_VBD measured_VBN to_TO obtain_VB means_VBZ and_CC standard_JJ deviations_NNS for_IN
          each_DT isotype_NN (_( Fig_NNP ._. 5_LS )_) ._. There_EX was_VBD no_DT difference_NN in_IN tubulin_NN
          isotype_NN levels_NNS in_IN normal_JJ and_CC tumor_NN tissues_NNS ._. The_DT
          predominant_NN isotype_NN fraction_NN was_VBD β-tubulin_JJ class_NN II_NNP (_( 0_CD ._. 58_CD
          ±_NN 0_CD ._. 09_CD of_IN the_DT total_JJ )_) ._. Both_DT β-tubulin_JJ classes_NNS III_NNP and_CC I_PRP +_NN
          IV_NNP were_VBD expressed_VBN in_IN smaller_JJR amounts_NNS in_IN all_DT tissues_NNS (_( 0_CD ._. 17_CD
          ±_NN 0_CD ._. 08_CD and_CC 0_CD ._. 26_CD ±_NN 0_CD ._. 08_CD ,_, respectively_RB )_) ._. Figures_NNS 5_CD Aand_NNP
          5_CD Bshow_NNP β-tubulin_JJ classes_NNS I_PRP +_NN IV_NNP and_CC II_NNP plotted_VBD as_IN a_DT
          percentage_NN of_IN total_JJ tubulin_NN (_( excluding_VBG β-tubulin_JJ class_NN
          III_NNP ,_, as_IN discussed_VBN above_IN )_) ,_, showing_VBG that_IN in_IN each_DT tissue_NN
          sample_NN β-tubulin_JJ class_NN II_NNP predominated_JJ ._. Figure_NN 5_CD Cshows_NNP
          the_DT distribution_NN of_IN β-tubulin_JJ class_NN III_NNP ._. Several_JJ samples_NNS
          had_VBD relatively_RB high_JJ levels_NNS of_IN β-tubulin_JJ class_NN III_NNP ._. Two_CD of_IN
          these_DT ,_, N_NNP 16_CD and_CC T_NN 18_CD ,_, were_VBD examined_VBN by_IN immunohistochemistry_NN
          to_TO determine_VB whether_IN the_DT high_JJ level_NN of_IN β-tubulin_JJ class_NN
          III_NNP might_MD be_VB due_JJ to_TO upregulation_NN of_IN this_DT isotype_NN in_IN tumor_NN
          or_CC normal_JJ cells_NNS ;_: however_RB ,_, as_IN discussed_VBN above_IN ,_, only_RB
          stromal_NN staining_VBG was_VBD observed_VBN ._.
          The_DT fraction_NN of_IN β-tubulin_JJ class_NN II_NNP in_IN tissues_NNS varied_VBD
          from_IN 0_CD ._. 41_CD to_TO 0_CD ._. 76_CD (_( Fig_NNP ._. 6_CD )_) ._. Figure_NN 6_CD Ashows_NNP the_DT similar_JJ
          distributions_NNS of_IN β-tubulin_JJ class_NN II_NNP in_IN both_DT normal_JJ and_CC
          tumor_NN tissues_NNS ._. Figure_NN 6_CD Bindicates_NNP the_DT relative_JJ
          frequencies_NNS of_IN fractions_NNS of_IN β-tubulin_JJ class_NN II_NNP ,_,
          demonstrating_VBG a_DT Gaussian_NNP distribution_NN for_IN the_DT tissue_NN
          samples_NNS ._. Student_NN 
          t_NN -_: tests_NNS comparing_VBG normal_JJ and_CC tumor_NN
          tissue_NN samples_NNS showed_VBD no_DT difference_NN in_IN mean_NN fraction_NN of_IN
          β-tubulin_JJ class_NN II_NNP (_( 0_CD ._. 60_CD ±_NN 0_CD ._. 10_CD and_CC 0_CD ._. 56_CD ±_NN 0_CD ._. 07_CD for_IN tumor_NN
          and_CC normal_JJ tissues_NNS ,_, 
          t_NN =_SYM -_: 1_CD ._. 454_CD and_CC 
          P_NN =_SYM 0_CD ._. 15_CD )_) ._. (_( Student_NNP 
          t_NN -_: tests_NNS for_IN tumor_NN versus_CC normal_JJ
          β-tubulin_JJ classes_NNS III_NNP or_CC I_PRP +_NN IV_NNP also_RB showed_VBD no_DT
          significant_JJ difference_NN :_: 
          t_NN =_SYM 0_CD ._. 776_CD ,_, 
          P_NN =_SYM 0_CD ._. 44_CD ;_: and_CC 
          t_NN =_SYM 0_CD ._. 741_CD ,_, 
          P_NN =_SYM 0_CD ._. 46_CD ._. )_) The_DT varying_VBG amounts_NNS of_IN
          isotypes_NNS in_IN these_DT tissue_NN samples_NNS suggest_VBP that_IN isotype_NN
          levels_NNS might_MD be_VB correlated_JJ with_IN other_JJ biomarkers_NNS of_IN poor_JJ
          prognosis_NN ._.
        
        
          Correlation_NNP of_IN β-tubulin_JJ isotype_NN protein_NN and_CC mRNA_NN
          levels_NNS
          To_TO establish_VB whether_IN β-tubulin_JJ isotype_NN protein_NN levels_NNS
          could_MD be_VB inferred_VBN from_IN mRNA_NN levels_NNS ,_, we_PRP used_VBD quantitative_JJ
          real-time_JJ PCR_NNP to_TO measure_VB β-tubulin_JJ mRNA_NN levels_NNS in_IN
          selected_VBN breast_NN tissues_NNS (_( Table_NNP 1_CD :_: T_NN 1_CD ,_, N_NNP 1_CD ,_, T_NN 4_CD ,_, N_NNP 4_CD ,_, T_NN 12_CD ,_,
          N_NNP 12_CD ,_, T_NN 13_CD ,_, N_NNP 13_CD ,_, T_NN 15_CD ,_, N_NNP 15_CD ,_, T_NN 18_CD ,_, N_NNP 18_CD ,_, N_NNP 6_CD ,_, and_CC T_NN 14_CD )_) (_( Fig_NNP ._. 7_CD )_) ._.
          These_DT data_NNS show_VBP a_DT broad_JJ distribution_NN of_IN mRNA_NN content_NN for_IN
          all_DT seven_CD β-tubulin_JJ isotype_NN classes_NNS ._. The_DT lowest_JJS levels_NNS
          were_VBD found_VBN for_IN β-tubulin_JJ classes_NNS IVa_NNP and_CC VI_NNP ._. The_DT ranges_NNS
          of_IN tubulin_NN levels_NNS for_IN the_DT other_JJ five_CD isotype_NN classes_NNS were_VBD
          similar_JJ ._. Although_IN differences_NNS between_IN matched_VBN tumor_NN and_CC
          normal_JJ tissues_NNS were_VBD found_VBN ,_, there_EX were_VBD no_DT correlations_NNS
          suggesting_VBG the_DT upregulation_NN or_CC downregulation_NN of_IN specific_JJ
          tubulin_NN isotypes_NNS in_IN tumor_NN tissues_NNS compared_VBN with_IN normal_JJ
          (_( data_NNS not_RB shown_VBN )_) ._. When_WRB the_DT fraction_NN of_IN mRNA_NN for_IN β-tubulin_JJ
          classes_NNS I_PRP +_NN IV_NNP ,_, II_NNP ,_, and_CC III_NNP were_VBD plotted_VBD against_IN the_DT
          corresponding_JJ fraction_NN of_IN protein_NN ,_, it_PRP became_VBD evident_JJ that_IN
          there_EX is_VBZ no_DT correlation_NN between_IN tubulin_NN mRNA_NN and_CC protein_NN
          levels_NNS in_IN these_DT tissues_NNS (_( Fig_NNP ._. 8_CD )_) ._.
        
        
          Comparison_NNP of_IN Her_PRP$ 2_CD /_NN neu_NN and_CC β-tubulin_JJ class_NN II_NNP
          expression_NN
          In_IN an_DT attempt_NN to_TO understand_VB the_DT significance_NN of_IN the_DT
          distributions_NNS of_IN β-tubulin_JJ classes_NNS II_NNP and_CC I_PRP +_NN IV_NNP in_IN
          normal_JJ and_CC tumor_NN breast_NN tissues_NNS ,_, we_PRP used_VBD ELISAs_NNP to_TO
          quantify_VB the_DT Her_PRP$ 2_CD /_NN neu_NN protein_NN levels_NNS in_IN these_DT tissues_NNS ._.
          Expression_NNP of_IN Her_PRP$ 2_CD /_NN neu_NN is_VBZ amplified_VBN in_IN 30_CD %_NN of_IN all_DT breast_NN
          tumors_NNS and_CC data_NNS suggest_VBP that_IN it_PRP might_MD be_VB a_DT negative_JJ
          prognostic_JJ indicator_NN [_NN 48_CD ]_NN ._. Figure_NN 9_CD Ashows_NNP the_DT levels_NNS
          of_IN Her_PRP$ 2_CD /_NN neu_NN protein_NN normalized_JJ for_IN total_JJ protein_NN in_IN tumor_NN
          and_CC normal_JJ tissues_NNS ._. Higher_JJR Her_PRP$ 2_CD /_NN neu_NN levels_NNS were_VBD found_VBN in_IN
          all_DT tumor_NN tissues_NNS compared_VBN with_IN normal_JJ tissues_NNS ._. This_DT
          result_NN verifies_NNS the_DT pathology_NN reports_NNS (_( Table_NNP 1_LS )_) that_WDT
          describe_VBP the_DT tumor_NN samples_NNS as_IN tumors_NNS ._. Note_VB that_IN one_CD
          '_POS normal_JJ '_POS tissue_NN ,_, N_NNP 12_CD ,_, was_VBD shown_VBN to_TO have_VB relatively_RB high_JJ
          levels_NNS of_IN Her_PRP$ 2_CD /_NN neu_NN protein_NN ._. However_RB ,_, an_DT independent_JJ
          pathology_NN report_NN on_IN this_DT tissue_NN sample_NN indicated_VBD a_DT
          significant_JJ number_NN of_IN tumor_NN cells_NNS throughout_IN the_DT entire_JJ
          breast_NN tissue_NN ,_, even_RB though_IN the_NNP '_POS normal_JJ '_POS sample_NN was_VBD
          excised_VBN at_IN a_DT site_NN distant_JJ from_IN the_DT tumor_NN ._.
          The_DT increase_NN of_IN Her_PRP$ 2_CD /_NN neu_NN protein_NN in_IN tumor_NN tissues_NNS
          compared_VBN with_IN normal_JJ tissues_NNS is_VBZ shown_VBN in_IN Fig_NNP ._. 9_CD Bto_NNP be_VB
          from_IN 5_CD -_: fold_VB to_TO more_JJR than_IN 30_CD -_: fold_VB ._. The_DT inset_NN in_IN Fig_NNP ._.
          9_CD Acompares_NNP Her_PRP$ 2_CD /_NN neu_NN protein_NN levels_NNS in_IN a_DT breast_NN cancer_NN
          cell_NN line_NN that_IN overexpresses_NNS Her_PRP$ 2_CD /_NN neu_NN with_IN one_CD that_WDT does_VBZ
          not_RB ._. The_DT increase_NN in_IN the_DT Her_PRP$ 2_CD /_NN neu_NN overexpressing_VBG cells_NNS is_VBZ
          more_JJR than_IN 40_CD -_: fold_VB ._. We_PRP infer_NN from_IN these_DT data_NNS that_IN the_DT
          breast_NN tumor_NN tissues_NNS approaching_VBG this_DT level_NN of_IN Her_PRP$ 2_CD /_NN neu_NN
          expression_NN would_MD have_VB significantly_RB increased_VBN Her_PRP$ 2_CD /_NN neu_NN
          levels_NNS ._. Plots_NNP of_IN Her_PRP$ 2_CD /_NN neu_NN protein_NN (_( Fig_NNP ._. 10_CD A_DT )_) or_CC fold_VB
          increase_NN in_IN Her_PRP$ 2_CD /_NN neu_NN protein_NN (_( Fig_NNP ._. 10_CD B_NNP )_) against_IN β-tubulin_JJ
          class_NN II_NNP fraction_NN demonstrate_VBP no_DT significant_JJ correlation_NN ._.
          There_EX is_VBZ therefore_RB no_DT relationship_NN between_IN tubulin_NN
          isotype_NN levels_NNS and_CC Her_PRP$ 2_CD /_NN neu_NN protein_NN expression_NN ._.
        
      
      
        Discussion_NNP
        
          β-_NN Tubulin_NNP class_NN II_NNP predominates_NNS in_IN breast_NN
          tissues_NNS
          This_DT is_VBZ the_DT first_JJ quantitative_JJ comparison_NN of_IN tubulin_NN
          isotype_NN protein_NN levels_NNS in_IN human_JJ tissues_NNS ._. Previous_JJ work_NN
          has_VBZ indicated_VBN that_IN vertebrate_NN tissues_NNS vary_VBP in_IN their_PRP$
          tubulin_NN isotype_NN composition_NN ._. β-_NN Tubulin_NNP class_NN II_NNP
          predominates_NNS in_IN brain_NN tissues_NNS and_CC has_VBZ been_VBN found_VBN in_IN
          smaller_JJR amounts_NNS in_IN other_JJ tissues_NNS [_NN 19_CD 45_CD ]_NN ._. Classes_NNS III_NNP
          and_CC IVa_NNP are_VBP primarily_RB found_VBN in_IN neurons_NNS ,_, whereas_IN classes_NNS I_PRP
          and_CC IVb_NNP are_VBP found_VBN in_IN many_JJ tissues_NNS [_NN 10_CD 19_CD ]_NN ._. β-_NN Tubulin_NNP
          class_NN V_NNP is_VBZ present_JJ in_IN small_JJ amounts_NNS in_IN many_JJ cell_NN types_NNS [_NN
          11_CD ]_NN and_CC class_NN VI_NNP is_VBZ found_VBN in_IN blood_NN cells_NNS and_CC
          hematopoietic_JJ tissues_NNS [_NN 49_CD 50_CD ]_NN ._. Much_JJ of_IN this_DT
          quantitative_JJ work_NN was_VBD done_VBN by_IN comparing_VBG mRNA_NN levels_NNS ._.
          However_RB ,_, mRNA_NN and_CC protein_NN levels_NNS are_VBP not_RB correlated_JJ for_IN
          many_JJ human_NN and_CC yeast_NN proteins_NNS ,_, especially_RB those_DT that_WDT are_VBP
          regulated_VBN by_IN post-transcriptional_JJ processes_VBZ [_NN 51_CD 52_CD 53_CD ]_NN
          ,_, although_IN there_EX is_VBZ controversy_NN regarding_VBG correct_JJ
          statistical_JJ analysis_NN and_CC interpretation_NN of_IN some_DT of_IN these_DT
          data_NNS [_NN 54_CD ]_NN ._. Intracellular_NNP tubulin_NN levels_NNS are_VBP under_IN both_DT
          transcriptional_NN and_CC post-transcriptional_JJ control_NN ._.
          Fine-tuning_NNP of_IN tubulin_NN levels_NNS during_IN the_DT cell_NN cycle_NN
          occurs_VBZ by_IN autoregulation_NN ._. This_DT process_NN alters_NNS mRNA_NN
          stability_NN and_CC requires_VBZ both_DT an_DT essential_JJ sequence_NN on_IN
          polysomal_NN β-tubulin_JJ mRNA_NN and_CC an_DT amino-terminal_JJ
          Met-_NNP Arg-_NNP Glu-_NNP Ile_NNP sequence_NN on_IN the_DT nascent_NN tubulin_NN
          polypeptide_NN [_NN 55_CD 56_CD 57_CD ]_NN ._. Furthermore_RB ,_, α-tubulin_JJ mRNA_NN
          levels_NNS remain_VBP high_JJ even_RB when_WRB protein_NN synthesis_NN is_VBZ
          repressed_VBN [_NN 58_CD ]_NN ._. In_IN fact_NN ,_, α-tubulin_JJ synthesis_NN in_IN CHO_NNP
          cells_NNS seems_VBZ to_TO have_VB a_DT role_NN in_IN regulating_VBG β-tubulin_JJ
          protein_NN levels_NNS ._.
          This_DT phenomenon_NN of_IN tubulin_NN post-transcriptional_JJ
          autoregu-lation_JJ was_VBD demonstrated_VBN in_IN a_DT wide_JJ variety_NN of_IN
          vertebrate_NN and_CC invertebrate_NN cell_NN types_NNS ._. It_PRP suggests_VBZ that_IN
          individual_JJ tubulin_NN isotype_NN protein_NN levels_NNS are_VBP all_DT
          similarly_RB regulated_VBN ,_, although_IN this_DT has_VBZ not_RB been_VBN
          demonstrated_VBN ._. Because_IN the_DT total_JJ amount_NN of_IN intracellular_NN
          tubulin_NN depends_VBZ on_IN both_DT mRNA_NN stability_NN and_CC protein_NN
          half-life_NN ,_, these_DT data_NNS together_RB indicate_VBP that_IN high_JJ levels_NNS
          of_IN tubulin_NN mRNA_NN might_MD be_VB associated_VBN with_IN low_JJ levels_NNS of_IN
          free_JJ tubulin_NN subunits_NNS ._. This_DT is_VBZ supported_VBN by_IN the_DT recent_JJ
          mass_NN spectrometry_NN and_CC isoelectric_JJ focusing_VBG work_NN that_WDT
          demonstrated_VBD a_DT lack_NN of_IN correlation_NN between_IN tubulin_NN
          isotype_NN protein_NN levels_NNS and_CC mRNA_NN levels_NNS in_IN
          paclitaxel-resistant_JJ cell_NN lines_NNS [_NN 59_CD ]_NN ._. However_RB ,_, tubulin_NN
          mRNA_NN levels_NNS are_VBP currently_RB interpreted_VBN by_IN most_JJS
          investigators_NNS as_RB directly_RB representing_VBG the_DT total_JJ
          intracellular_NN tubulin_NN protein_NN pool_NN ._. One_CD alternative_NN to_TO
          mRNA_NN quantification_NN is_VBZ immunostaining_VBG ._. Although_IN
          immunostaining_VBG of_IN cells_NNS is_VBZ useful_JJ for_IN localizing_VBG proteins_NNS
          in_IN tissues_NNS and_CC cells_NNS ,_, accurate_JJ quantification_NN by_IN this_DT
          method_NN is_VBZ difficult_JJ [_NN 41_CD ]_NN ._. Nevertheless_RB ,_, quantitative_JJ
          measurement_NN of_IN protein_NN levels_NNS is_VBZ crucial_JJ for_IN
          understanding_VBG intracellular_NN events_NNS ._. In_IN our_PRP$ studies_NNS ,_,
          quantitative_JJ real-time_JJ PCR_NNP data_NNS from_IN selected_VBN breast_NN
          tissue_NN samples_NNS revealed_VBD that_IN β-tubulin_JJ mRNA_NN and_CC protein_NN
          levels_NNS are_VBP not_RB correlated_JJ ._. These_DT results_NNS indicate_VBP that_IN
          quantitative_JJ studies_NNS of_IN β-tubulin_JJ isotypes_NNS that_WDT are_VBP done_VBN
          exclusively_RB with_IN PCR_NNP techniques_NNS should_MD be_VB interpreted_VBN
          with_IN caution_NN because_IN functional_JJ protein_NN levels_NNS cannot_NN be_VB
          inferred_VBN ._.
          Consistent_NNP with_IN our_PRP$ results_NNS is_VBZ the_DT finding_NN of_IN both_DT
          β-tubulin_JJ classes_NNS I_PRP and_CC II_NNP by_IN immunostaining_VBG in_IN many_JJ
          human_JJ tissues_NNS and_CC cell_NN types_NNS [_NN 60_CD ]_NN ._. To_TO understand_VB the_DT
          relationship_NN between_IN the_DT drug_NN target_NN levels_NNS and_CC the_DT
          development_NN of_IN drug_NN resistance_NN ,_, it_PRP is_VBZ essential_JJ to_TO know_VB
          the_DT actual_JJ protein_NN amounts_NNS in_IN tissues_NNS and_CC cells_NNS ._. We_PRP
          demonstrate_VBP here_RB by_IN a_DT quantitative_JJ ELISA_NNP assay_NN that_IN the_DT
          β-tubulin_JJ class_NN II_NNP protein_NN is_VBZ on_IN average_VB the_DT most_RBS
          abundant_JJ isotype_NN in_IN human_JJ breast_NN tissues_NNS ._. We_PRP found_VBD a_DT
          distribution_NN of_IN β-tubulin_JJ class_NN II_NNP levels_NNS ,_, ranging_VBG from_IN
          0_CD ._. 41_CD to_TO 0_CD ._. 76_CD ._. This_DT wide_JJ distribution_NN was_VBD not_RB expected_VBN ,_,
          because_IN our_PRP$ study_NN of_IN tubulin_NN isotypes_NNS in_IN pig_NN brains_NNS
          showed_VBD very_RB little_RB brain-to-brain_JJ variation_NN ._. To_TO evaluate_VB
          the_DT significance_NN of_IN the_DT distribution_NN of_IN β-tubulin_JJ classes_NNS
          II_NNP and_CC I_PRP +_NN IV_NNP in_IN breast_NN tissues_NNS ,_, we_PRP measured_VBD the_DT tissue_NN
          levels_NNS of_IN Her_PRP$ 2_CD /_NN neu_NN protein_NN ,_, known_VBN to_TO be_VB amplified_VBN in_IN 30_CD %_NN
          of_IN all_DT breast_NN tumors_NNS and_CC associated_VBN with_IN poor_JJ prognosis_NN [_NN
          48_CD ]_NN ._. All_DT tumor_NN tissues_NNS expressed_VBD higher_JJR levels_NNS of_IN
          Her_PRP$ 2_CD /_NN neu_NN relative_JJ to_TO normal_JJ tissues_NNS ._. However_RB ,_, there_EX was_VBD
          no_DT correlation_NN between_IN this_DT biomarker_NN and_CC levels_NNS of_IN
          β-tubulin_JJ classes_NNS II_NNP or_CC I_PRP +_NN IV_NNP isotype_NN levels_NNS ._. Thus_RB the_DT
          significance_NN of_IN the_DT range_NN of_IN isotype_NN levels_NNS in_IN breast_NN
          tissues_NNS remains_VBZ unknown_JJ ._. Although_IN it_PRP is_VBZ possible_JJ that_IN
          β-tubulin_JJ class_NN II_NNP levels_NNS might_MD be_VB correlated_JJ with_IN a_DT
          prognostic_JJ bio-marker_JJ not_RB yet_RB examined_VBD [_NN 61_CD ]_NN ,_, these_DT
          results_NNS suggest_VBP that_IN a_DT normal_JJ patient-to-patient_JJ
          variation_NN might_MD exist_VB ._.
          The_DT ELISA_NNP method_NN described_VBD here_RB involves_VBZ total_JJ
          extraction_NN of_IN tubulin_NN and_CC does_VBZ not_RB differentiate_VB between_IN
          polymeriz-able_JJ and_CC nonpolymerizable_JJ tubulin_NN fractions_NNS ._.
          There_EX are_VBP reports_NNS of_IN tubulin_NN isotypes_NNS that_WDT are_VBP
          differentially_RB incorporated_VBN into_IN microtubule_NN structures_NNS [_NN
          62_CD ]_NN ._. However_RB ,_, it_PRP is_VBZ not_RB possible_JJ to_TO fractionate_NN
          microtubules_NNS from_IN total_JJ cytoplasmic_JJ tubulin_NN with_IN
          quick-frozen_JJ human_JJ tissue_NN samples_NNS ._. Current_JJ experiments_NNS
          are_VBP exploring_VBG this_DT aspect_NN of_IN tubulin_NN isotype_NN utilization_NN
          in_IN cell_NN culture_NN studies_NNS ._. One_CD complexity_NN in_IN our_PRP$ work_NN is_VBZ
          the_DT sampling_VBG of_IN breast_NN tissue_NN ._. It_PRP is_VBZ possible_JJ that_IN
          samples_NNS are_VBP composed_VBN of_IN different_JJ amounts_NNS of_IN
          heterogeneous_JJ cell_NN types_NNS ._. However_RB ,_, because_IN our_PRP$ data_NNS show_VBP
          similar_JJ isotype_NN amounts_NNS in_IN normal_JJ and_CC tumor_NN breast_NN
          tissues_NNS ,_, differential_NN tissue_NN sampling_VBG seems_VBZ not_RB to_TO be_VB an_DT
          issue_NN in_IN these_DT experiments_NNS ._. Our_PRP$ method_NN is_VBZ based_VBN in_IN part_NN
          on_IN an_DT ELISA_NNP assay_NN developed_VBN by_IN Thrower_NNP and_CC colleagues_NNS [_NN
          63_CD ]_NN for_IN tubulin_NN extracts_NNS ._. This_DT work_NN fulfills_VBZ their_PRP$
          suggestion_NN to_TO quantify_VB changes_NNS in_IN tubulin_NN isotype_NN levels_NNS
          with_IN the_DT appropriate_JJ antibodies_NNS ,_, and_CC establishes_VBZ a_DT
          sensitive_JJ and_CC accurate_JJ assay_NN to_TO complement_VB mRNA_NN assays_NNS
          and_CC studies_NNS of_IN the_DT response_NN of_IN cultured_JJ cells_NNS to_TO
          antimitotic_JJ drugs_NNS ._.
          The_DT patient_NN diagnoses_NNS for_IN these_DT tumor_NN samples_NNS were_VBD
          most_RBS commonly_RB infiltrating_VBG ductal_NN carcinoma_NN (_( 12_CD of_IN 20_CD
          samples_NNS )_) ._. We_PRP found_VBD no_DT correlations_NNS between_IN tubulin_NN
          isotype_NN levels_NNS and_CC any_DT of_IN the_DT variables_NNS given_VBN in_IN the_DT
          pathology_NN reports_NNS (_( estrogen_NN receptor_NN ,_, progesterone_NN
          receptor_NN ,_, age_NN ,_, race_NN ,_, or_CC histology_NN grade_NN )_) ._. It_PRP should_MD be_VB
          noted_VBN that_IN the_NNP '_POS normal_JJ '_POS breast_NN tissues_NNS examined_VBD in_IN this_DT
          study_NN were_VBD excised_VBN from_IN a_DT site_NN distal_NN to_TO the_DT tumor_NN site_NN
          but_CC in_IN the_DT same_JJ breast_NN ._. Histological_NNP examination_NN of_IN the_NNP
          '_POS normal_JJ '_POS tissues_NNS indicates_VBZ the_DT presence_NN of_IN fibrocystic_JJ
          changes_NNS in_IN many_JJ of_IN the_DT samples_NNS and_CC therefore_RB ,_, although_IN
          these_DT changes_NNS are_VBP not_RB uncommon_JJ in_IN normal_JJ aging_NN ,_, they_PRP
          cannot_NN be_VB classified_VBN as_RB truly_RB '_POS normal_JJ '_POS breast_NN tissue_NN ._.
          However_RB ,_, independent_JJ pathology_NN reports_NNS determined_VBN that_IN
          the_NNP '_POS normal_JJ '_POS tissues_NNS were_VBD '_POS non-tumor_JJ '_POS tissues_NNS with_IN the_DT
          exception_NN of_IN N_NNP 1_CD ,_, N_NNP 12_CD ,_, and_CC N_NNP 13_CD ,_, in_IN which_WDT tumor_NN cells_NNS were_VBD
          noted_VBN ._. N_NNP 1_CD and_CC N_NNP 13_CD were_VBD estimated_VBN to_TO contain_VB more_JJR than_IN 5_CD %_NN
          tumor_NN cells_NNS ._. N_NNP 12_CD ,_, however_RB ,_, had_VBD tumor_NN cells_NNS throughout_IN the_DT
          breast_NN tissue_NN and_CC therefore_RB although_IN the_NNP '_POS normal_JJ '_POS sample_NN
          was_VBD taken_VBN distal_NN to_TO the_DT tumor_NN it_PRP contained_VBD significant_JJ
          numbers_NNS of_IN tumor_NN cells_NNS ._. N_NNP 12_CD was_VBD also_RB shown_VBN in_IN our_PRP$ ELISA_NNP
          studies_NNS to_TO have_VB relatively_RB high_JJ levels_NNS of_IN Her_PRP$ 2_CD /_NN neu_NN
          protein_NN ._. Thus_RB ,_, the_DT Her_PRP$ 2_CD /_NN neu_NN ELISAs_NNP provided_VBD a_DT second_JJ
          means_NNS of_IN grossly_RB differentiating_VBG between_IN '_POS tumor_NN '_'' and_CC

          '_POS normal_JJ '_POS tissues_NNS for_IN these_DT patients_NNS ._.
          It_PRP is_VBZ important_JJ to_TO note_VB that_IN many_JJ tumor_NN tissues_NNS do_VBP not_RB
          express_VB Her_PRP$ 2_CD /_NN neu_NN ;_: it_PRP is_VBZ therefore_RB not_RB a_DT generally_RB useful_JJ
          marker_NN for_IN differentiating_VBG between_IN tumor_NN and_CC normal_JJ
          tissues_NNS ._. In_IN addition_NN ,_, our_PRP$ work_NN demonstrates_VBZ that_IN although_IN
          β-tubulin_JJ class_NN III_NNP is_VBZ a_DT marker_NN for_IN aggressive_JJ
          neuroendocrine_NN tumors_NNS [_NN 36_CD 64_CD ]_NN ,_, it_PRP is_VBZ not_RB a_DT significant_JJ
          biomarker_NN in_IN breast_NN tumors_NNS ._. We_PRP speculate_VBP that_IN this_DT is_VBZ
          because_IN breast_NN tissue_NN rarely_RB dysregulates_NNS to_TO
          neuroendocrine_NN cell_NN types_NNS ._.
        
        
          Tumor_NNP and_CC normal_JJ breast_NN tissues_NNS have_VBP similar_JJ
          tubulin_NN isotype_NN levels_NNS
          Over_IN the_DT past_JJ decade_NN paclitaxel_NN and_CC docetaxel_NN have_VBP
          become_VBN important_JJ chemotherapeutic_JJ agents_NNS for_IN both_DT ovarian_NN
          and_CC breast_NN cancers_NNS [_NN 1_CD 2_CD ]_NN ._. Considerable_NNP interest_NN has_VBZ
          focused_VBN on_IN the_DT target_NN receptor_NN -_: tubulin_NN -_: and_CC mechanisms_NNS
          underlying_VBG efficacy_NN ,_, toxicity_NN ,_, and_CC drug_NN resistance_NN [_NN 7_CD 8_CD
          23_CD 24_CD 27_CD 28_CD ]_NN ._. Whether_IN tubulin_NN isotype_NN levels_NNS might_MD
          determine_VB cellular_JJ responses_NNS to_TO antimitotic_JJ agents_NNS
          remains_VBZ controversial_JJ ._. For_IN example_NN ,_, paclitaxel-resistant_JJ
          lung_NN cancer_NN cells_NNS and_CC ovarian_NN tumors_NNS were_VBD shown_VBN to_TO have_VB
          increased_VBN levels_NNS of_IN tubulin_NN isotypes_NNS ,_, particularly_RB
          β-tubulin_JJ classes_NNS III_NNP and_CC IVa_NNP [_NN 28_CD ]_NN ._. Furthermore_RB ,_, when_WRB
          paclitaxel-resistant_JJ lung_NN cancer_NN cells_NNS were_VBD treated_VBN with_IN
          antisense_NN oligonucleotides_NNS for_IN β-tubulin_JJ class_NN III_NNP ,_, the_DT
          drug_NN resistance_NN was_VBD partly_RB reversed_VBN ,_, coincident_JJ with_IN
          decreased_VBD protein_NN levels_NNS of_IN β-tubulin_JJ class_NN III_NNP [_NN 65_CD ]_NN ._.
          However_RB ,_, it_PRP should_MD be_VB noted_VBN that_IN β-tubulin_JJ classes_NNS I_PRP ,_, II_NNP ,_,
          III_NNP ,_, and_CC IVa_NNP all_DT increased_VBN significantly_RB in_IN
          paclitaxel-resistant_JJ lung_NN cancer_NN cells_NNS ,_, indicating_VBG that_IN
          the_DT drug_NN effect_NN did_VBD not_RB uniquely_RB involve_VB a_DT single_JJ tubulin_NN
          isotype_NN ._. In_IN other_JJ work_NN ,_, β-tubulin_JJ classes_NNS III_NNP and_CC IVa_NNP
          were_VBD shown_VBN to_TO increase_VB in_IN paclitaxel-resistant_JJ prostate_NN
          cancer_NN cells_NNS [_NN 29_CD ]_NN ._. However_RB ,_, these_DT two_CD isotypes_NNS
          continued_VBD to_TO be_VB expressed_VBN in_IN the_DT lowest_JJS amounts_NNS ._.
          In_IN ovarian_NN cancer_NN cells_NNS ,_, mutations_NNS in_IN residues_NNS near_IN
          the_DT putative_JJ paclitaxel-binding_JJ site_NN of_IN β-tubulin_JJ class_NN I_PRP
          were_VBD found_VBN in_IN paclitaxel-resistant_JJ ovarian_NN cancer_NN cells_NNS [_NN
          23_CD ]_NN ._. Other_JJ work_NN suggests_VBZ that_IN changes_NNS in_IN tubulin_NN
          isotypes_NNS alone_RB cannot_NN confer_VB resistance_NN to_TO antimitotics_NNS ._.
          It_PRP was_VBD demonstrated_VBN that_IN one_CD group_NN of_IN antimitotic_JJ agents_NNS ,_,
          vinca_NN alkaloids_NNS ,_, bind_NN with_IN similar_JJ affinity_NN to_TO all_DT
          β-tubulin_JJ isotypes_NNS [_NN 12_CD ]_NN ,_, thus_RB suggesting_VBG for_IN therapy_NN
          with_IN vinorelbine_NN ,_, vinblas-tine_JJ ,_, or_CC vincristine_NN that_DT
          tubulin_NN isotype_NN levels_NNS are_VBP incidental_JJ for_IN efficacy_NN ._.
          Furthermore_RB ,_, transfection_NN of_IN CHO_NNP cells_NNS with_IN β-tubulin_JJ
          classes_NNS I_PRP ,_, II_NNP ,_, or_CC IVb_NNP did_VBD not_RB produce_VB resistance_NN to_TO
          paclitaxel_NN [_NN 32_CD ]_NN ._. The_DT alternative_JJ hypothesis_NNS ,_, derived_VBN
          from_IN the_DT work_NN of_IN Cabral_NNP and_CC colleagues_NNS ,_, is_VBZ that_IN rather_RB
          than_IN the_DT tubulin_NN isotype_NN levels_NNS ,_, the_DT amount_NN of_IN
          polymerized_JJ tubulin_NN is_VBZ the_DT critical_JJ factor_NN that_WDT regulates_VBZ
          response_NN to_TO antimitotic_JJ drugs_NNS ._. For_IN example_NN ,_, total_JJ amounts_NNS
          of_IN polymerizable_JJ tubulin_NN are_VBP decreased_VBN in_IN
          paclitaxel-resistant_JJ cells_NNS ,_, whereas_IN col-cemid-resistant_JJ
          tubulin_NN or_CC vinca_NN alkaloid-resistant_JJ cells_NNS have_VBP increased_VBN
          levels_NNS of_IN assembled_VBN tubulin_NN [_NN 34_CD 66_CD 67_CD ]_NN ._. Furthermore_RB ,_,
          when_WRB cells_NNS were_VBD transfected_JJ with_IN β-tubulin_JJ class_NN III_NNP ,_,
          weak_JJ resistance_NN to_TO paclitaxel_NN was_VBD found_VBN ,_, and_CC this_DT
          resistance_NN was_VBD associated_VBN with_IN decreased_VBD microtubule_NN
          stability_NN [_NN 68_CD ]_NN ._. This_DT is_VBZ consistent_JJ with_IN the_DT different_JJ
          modes_NNS of_IN action_NN of_IN these_DT drugs_NNS :_: paclitaxel_NN stabilizes_VBZ
          microtubules_NNS and_CC colcemid_NN inhibits_NNS tubulin_NN assembly_NN ._. In_IN
          support_NN of_IN this_DT hypothesis_NNS ,_, tubulin_NN mutations_NNS consistent_JJ
          with_IN altered_VBN assembly_NN properties_NNS have_VBP been_VBN identified_VBN in_IN
          paclitaxel-resistant_JJ and_CC vinca_NN alkaloid-resistant_JJ cells_NNS [_NN
          33_CD 66_CD 69_CD ]_NN ._.
        
      
      
        Conclusion_NNP
        We_PRP demonstrate_VBP that_IN normal_JJ and_CC tumor_NN breast_NN tissues_NNS ,_,
        before_IN chemotherapy_NN or_CC radiation_NN treatment_NN ,_, have_VBP broad_JJ
        distributions_NNS of_IN β-tubulin_JJ isotypes_NNS ._. Furthermore_RB ,_, β_NN class_NN
        II_NNP tubulin_NN predominates_NNS in_IN most_JJS breast_NN tissues_NNS ._. The_DT
        β-tubulin_JJ isotype_NN levels_NNS in_IN normal_JJ and_CC tumor_NN tissue_NN are_VBP not_RB
        significantly_RB different_JJ and_CC are_VBP therefore_RB unlikely_JJ to_TO
        contribute_VB to_TO differential_NN responses_NNS of_IN tumors_NNS to_TO
        antimitotic_JJ agents_NNS ._. The_DT initial_JJ drug_NN sensitivity_NN might_MD
        depend_VB upon_IN the_DT levels_NNS of_IN polymerized_JJ tubulin_NN in_IN normal_JJ
        versus_CC tumor_NN tissues_NNS associated_VBN with_IN the_DT differential_NN
        expression_NN of_IN MAPs_NNP and_CC dynamics_NNS regulators_NNS such_JJ as_IN stathmin_NN
        [_NN 70_CD ]_NN ,_, a_DT hypothesis_NNS currently_RB being_VBG explored_JJ in_IN our_PRP$
        laboratory_NN ._. The_DT work_NN presented_VBN here_RB describes_VBZ untreated_JJ
        tumors_NNS and_CC should_MD be_VB useful_JJ for_IN comparison_NN with_IN
        paclitaxel-treated_JJ tumors_NNS as_IN a_DT basis_NN for_IN evaluating_VBG tubulin_NN
        isotype_NN levels_NNS in_IN response_NN to_TO therapy_NN or_CC in_IN the_DT development_NN
        of_IN drug_NN resistance_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        BCIP_NNP =_SYM 5_CD -_: bromo-_NN 4_CD -_: chloroindol-_NN 3_CD -_: yl_NN phosphate_NN ;_: cDNA_NN =_SYM
        complementary_JJ DNA_NNP ;_: EGTA_NNP =_SYM (_( ethylene-bis_JJ
        [_NN oxyethylenenitrilo_NN ]_NN )_) tetraacetic_JJ acid_NN ;_: CHTN_NNP =_SYM Cooperative_NNP
        Human_NNP Tissue_NNP Network_NNP ;_: ELISA_NNP =_SYM enzyme-linked_JJ immunosorbent_NN
        assay_NN ;_: MAP_NNP =_SYM microtubule_NN associated_VBN protein_NN ;_: MES_NNP =_SYM 2_CD -_: (_( 
        N_NNP -_: morpholino_NN )_) -_: ethane_NN sulfonic_JJ acid_NN ;_:
        NBT_NNP =_SYM nitro_NN blue_JJ tetrazolium_NN ;_: PBS_NNP =_SYM phosphate-buffered_JJ
        saline_NN ;_: PC-tubulin_NNP =_SYM MAP-free_NNP phosphocellulose-purified_JJ
        tubulin_NN ;_: PCR_NNP =_SYM polymerase_NN chain_NN reaction_NN ;_: PIPES_NNP =_SYM
        piperazine-_NN 
        N_NNP ,_, N_NNP '_POS -_: bis_NNS (_( 2_CD -_: ethanesulfonic_JJ acid_NN )_) ;_:
        PVDF_NNP =_SYM poly_RB (_( vinylidene_NN difluoride_NN )_) ._.
      
    
  
